Locus 23: UGT1A1 (2q37.1)
EA = effect allele; OA = other allele; EAF = frequency of effect allele;
| Summary of biological annotations |
| SNP | rs887829 |
| Chromosomal location | Chr2: 234,333,309 (2q37.1) |
| Gene (distance) | UGT1A1 (-348) |
| Predicted causal gene | UGT1A1 |
| Gene/protein classification | metabolic enzyme |
| Metabolite (Pathway) | biliverdin (Hemoglobin and porphyrin metabolism; Cofactors and vitamins) |
| Biochemical locus-metabolite relationship | UGT1A1 encodes an enzyme with bilirubin glucuronidating activity [1898728]. Bilirubin is derived from biliverdin. |
| eQTL associations | - |
| Medical information |
| Complex trait associations | Bilirubin levels [21646302,23371916,19419973,22085899,19414484]; Cholelithiasis-related traits in sickle cell anemia [22558097]; Circulating cell-free DNA [22511988]; |
| Known metabolite associations | bilirubin (E,E)*/oleoylcarnitine [21886157]; X-11530,X-11441,X-11793,X-11442 [23093944]; Xanthurenate [23823483] |
| Inborn error of metabolism | Crigler-Najjar syndrome (CNS); Gilbert's syndrome |
| Pharmacological information |
| ChEMBL ID | CHEMBL1287617 |
| Drug information |
Substrate: Irinotecan is a topoisomerase I inhibitor used primarily to treat colorectal cancer. The UGT1A1*28 allele has been associated to toxicity.
|
| Locus information for top associated metabolite |
HapMap2 imputation | 1KGP imputation |

